Table 2.
Secondary outcomes: baseline through 12-month follow-up (M/s.d.)
| FBT (N = 51) | CBT-E (N = 46) | Sign | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FBT lower weight (n = 21) | FBT higher weight (n = 30) | CBT-E lower weight (n = 16) | CBT-E higher weight (n = 30) | ||||||||||||||
| B | EOT | 6 m | 12 m | B | EOT | 6 m | 12 m | B | EOT | 6 m | 12 m | B | EOT | 6 m | 12 m | ||
| Primary outcome | |||||||||||||||||
| %mBMI | 82.8 | 96.8a | 95.3 | 96.2 | 102.9 | 112.6b | 111.5 | 108.8 | 84.1 | 94.4a | 94.4 | 96.4 | 104.5 | 108.3b | 109.7 | 107.2 | p < 0.001a |
| p < 0.001b | |||||||||||||||||
| EDE/Q-G | 1.9 | 0.9 | 0.7 | 0.5 | 1.5 | 0.2 | 0.1 | 0.3 | 3.3 | 1.2 | 1.3 | 0.8 | 3.1 | 1.2 | 1.1 | 1.5 | NS |
| 1.5 | 1.4 | 1.2 | 0.9 | 1.3 | 0.3 | 0.2 | 0.3 | 1.1 | 1.0 | 1.4 | 0.4 | 1.5 | 1.5 | 1.2 | 1.7 | NS | |
| Secondary outcomes | |||||||||||||||||
| BAI | 15.4 | 12.4 | 5.3 | 8.9 | 10.8a | 3.9b | 5.1 | 4.4 | 19.1 | 7.4 | 7.9 | 6.0 | 18.9a | 12.7b | 12.6 | 12.4 | NS |
| 10.7 | 11.2 | 7.2 | 11.1 | 8.6 | 4.8 | 6.0 | 4.0 | 12.9 | 5.7 | 6.5 | 4.4 | 12.7 | 12.7 | 12.3 | 13.0 | MEa,b | |
| CIA | 17.5 | 7.1 | 5.5 | 4.9 | 11.1a | 2.1 | 2.7 | 6.2 | 29.0 | 7.5 | 7.9 | 3.8 | 25.5a | 7.1 | 9.0 | 12.1 | NS |
| 12.4 | 9.4 | 10.1 | 8.7 | 10.0 | 4.4 | 5.5 | 8.2 | 11.4 | 7.3 | 7.8 | 2.6 | 12.9 | 9.6 | 11.0 | 15.9 | MEa | |
| CDI-2 | 55.4 | 50.3 | 46.6 | 47.0 | 57.0a | 47.1 | 46.6 | 44.5c | 64.5 | 48.9 | 56.3 | 51.0 | 66.4a | 52.1 | 54.2 | 58.4c | NS |
| 13.7 | 9.2 | 8.0 | 10.1 | 15.1 | 6.8 | 7.3 | 6.2 | 11.4 | 5.5 | 16.4 | 10.9 | 13.3 | 10.4 | 11.0 | 16.9 | MEa,c | |
| BSI | 50.7 | 49.0 | 45.1 | 48.7 | 48.0 | 49.2 | 46.0 | 43.3 | 49.3 | 48.1 | 43.5 | 42.8 | 51.5 | 50.1 | 52.0 | 46.7 | NS |
| 11.4 | 9.0 | 11.3 | 11.4 | 13.4 | 11.6 | 11.9 | 11.1 | 10.6 | 7.7 | 6.8 | 6.9 | 11.7 | 11.2 | 11.4 | 8.5 | NS | |
| RSE | 18.9 | 20.4 | 22.1 | 19.9 | 19.4a | 24.1b | 25.2d | 20.3 | 11.6 | 18.9 | 19.4 | 19.5 | 11.5a | 19.9b | 17.3d | 16.5 | NS |
| 7.9 | 6.1 | 6.2 | 8.8 | 7.4 | 4.5 | 5.7 | 9.4 | 5.5 | 4.7 | 7.2 | 8.5 | 5.5 | 6.0 | 7.0 | 5.3 | MEa,b,d | |
| FAD | 18.8 | 19.7 | 19.3 | 18.1 | 21.6 | 21.7 | 21.3 | 20.7 | 24.1 | 20.1 | 24.8 | 18.3 | 23.9 | 22.8 | 21.9 | 23.4 | NS |
| 4.3 | 5.8 | 4.6 | 3.3 | 5.4 | 6.4 | 6.3 | 5.0 | 4.5 | 5.7 | 7.2 | 2.1 | 6.0 | 4.7 | 4.9 | 2.6 | NS | |
| CBCLT | 54.7 | 50.1 | 42.9 | 48.0 | 54.8 | 45.2 | 45.4 | 43.7c | 57.0 | 46.9 | 48.3 | 48.8 | 59.1 | 50.9 | 49.0 | 53.4c | NS |
| 12.1 | 9.9 | 11.0 | 12.6 | 10.6 | 13.1 | 11.0 | 10.8 | 9.4 | 9.7 | 11.5 | 11.0 | 10.8 | 11.7 | 14.1 | 9.1 | MEc | |
EDE/Q-G, Eating Disorder Examination (or Questionnaire) Global Score; BAI, Beck Anxiety Inventory; CIA, Clinical Impairment Assessment; CDI-2, Child Depression Inventory; BSI, Brief Symptom Inventory; RSE, Rosenberg Self-Esteem Scale; FAD, Family Assessment Device; CBCLT, Child Behavior Checklist Total Score.
Key: Primary outcome = slope of weight gain (%mBMI) and main effect for treatment (EDE/Q) at EOT; ME = main effect; ME refers to comparison between FBT and CBT-E at each time point, i.e.: aBaseline (B) comparison of %mBMI between treatments, separately by weight cohort; bEOT comparison; c12-month follow-up (12 m) comparison; d6-month follow-up (6 m) comparison.
Int = interaction effect, that is, treatment by visit interaction; and NS = no significant ME or interaction; superscript refers to ME at time point, e.g. baseline, EOT, etc.
Bold p-values = statistical significance.